VolitionRx Limited
AMEX: VNRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange American
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Cameron Reynolds
- Employees
- 85
- Headquarters
- Henderson, United States
- IPO year
- 2012
- Market cap
- $8.4M
- Website
- https://www.volition.com
Loading VNRX…
Loading profile data…Frequently asked questions about VNRX
What does VolitionRx Limited (VNRX) do?
VolitionRx Limited is an international epigenetics firm that specializes in pioneering advanced blood tests. These diagnostics are developed to aid in the global detection of various cancers and other diseases. Their innovative product suite includes Nu.Q, engineered for cancer detection; Nu.Q Nets, which monitors immune system health; Nu.Q Vet,...
Where does VNRX trade?
VolitionRx Limited (VNRX) trades on the New York Stock Exchange American.
What sector is VNRX in?
VolitionRx Limited (VNRX) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of VolitionRx Limited?
Cameron Reynolds is the chief executive officer of VolitionRx Limited (VNRX).
Where is VolitionRx Limited headquartered?
VolitionRx Limited is headquartered in United States.
Does VNRX pay a dividend?
VolitionRx Limited (VNRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VNRX go public?
VolitionRx Limited (VNRX) completed its initial public offering in 2012.